1 / 25

Massachusetts Biotechnology Coalition Contract Issues for Biotech Attorneys Thursday, March 12, 2009

Massachusetts Biotechnology Coalition Contract Issues for Biotech Attorneys Thursday, March 12, 2009. Agenda: Introductions: C. Elizabeth O’Keeffe, JD, MPH, CHC Maria D. Buckley, Of Counsel, Nutter McClennen & Fish, LLP Stephen B. Harris, Life Sciences Sr. Specialist, Chubb & Son

Gabriel
Télécharger la présentation

Massachusetts Biotechnology Coalition Contract Issues for Biotech Attorneys Thursday, March 12, 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Massachusetts Biotechnology CoalitionContract Issues for Biotech AttorneysThursday, March 12, 2009 • Agenda: • Introductions: • C. Elizabeth O’Keeffe, JD, MPH, CHC • Maria D. Buckley, Of Counsel, Nutter McClennen & Fish, LLP • Stephen B. Harris, Life Sciences Sr. Specialist, Chubb & Son • Colleen Surrette Sproul,JD, Principal, Contracts, Associates, Inc. • What contracts? (E. O’Keeffe) • Boilerplate (E. O’Keeffe) • Transactional Contracts; Funky Clauses (M. Buckley) • Insurance and Indemnification (S. Harris) • In-House Perspective; Triage; Resources (C. Sproul) • Q:A

  2. What Contracts?

  3. DSMB SPONSOR Services Agreements CTA CTA CTAs CRO* INSTITUTION/ CLINICAL SITE *Contracts on behalf of sponsor (donated by dotted line) INVESTIGATOR Blue = CTA Orange = Service Agreement Green = Regulatory “agreement” Informed Consent 1572 **May or may not be a written agreement - depends on whether IRB is commercial, local, centralized, etc FDA SUBJECT IRB** Third party vendors (e.g., labs)

  4. CRO Contract Issues • Sponsor may want CRO to handle CTAs because of: • Speed • Cost • Strength of CRO’s relationships with research sites/investigators • However, Sponsors may have problems with CROs protecting Sponsors’ interests? • CRO sometimes want to get contract in place quickly and not expend resources in lengthy negotiations • CRO may not have adequate legal expertise

  5. CRO Contract Issues • If CRO is allowed to contract on the Sponsor’s behalf, contractual controls can help protect Sponsor’s interests • Range of Possibilities • CTA template • Sponsor provides template for CRO use • CRO provides CTA template for Sponsor review and approval • CRO authority to negotiate • Only extends to certain provisions • CRO must submit all changes to Sponsor for review and approval • Notification of changes and amendments

  6. Thesis Traditionally, lawyers use the term “boilerplate” to refer to any standardized, “one size fits all” provision Classic examples: The choice of law provision The notice provision The force majeure provision The assignment and delegation provision Provisions: Supply a road map Serve housekeeping functions (matters of secondary importance) “Boilerplate” is a misnomer as applied to these provisions and that lying in wait within each of them are significant business and legal issues.

  7. Agenda Anatomy of a contract Standard sections Recommended language Practical, operational and legal perspectives

  8. Recitals Recitals (a/k/a “WHEREAS clauses”) supply helpful context. Describe the who, why and how. A very high-level synopsis of the agreement and provide a framework for interpretation of the agreement by the parties and/or the court. Recitals are non-binding, unless specifically incorporated. “The recitals shall be incorporated by reference in this agreement as if full set forth herein.”

  9. MAGI Approachwww.firstclinical.com • Parties & Recitals • __________ (“Sponsor”), a {form of entity} organized under the laws of {State}, __________ (“Site”), a {form of entity} organized under the laws of {State}, and __________ (“Investigator”), Site’s {employee/contractor}, enter into this Agreement (“Agreement”) whereby Sponsor engages Site and Investigator to conduct clinical research on ______________ (“Study {Drug/Device/Biologic}”) according to the provisions of this Agreement and Protocol __________.[1,2,3,4,5,6,7,8,9]

  10. Term & Termination Term: Effective date As of a specified date or Upon execution by last party to sign Automatic termination (a.k.a. “Expiration”) Specific date Completion of all study related activities “End of study” needs to be clarified IRB closure at site? Sponsor close out visit? Data analysis from all sites in multi-center study?

  11. Term & Termination (Cont.) Initiated termination: Sponsor: Generally 3-5 different ways for Sponsor to terminate Includes a ‘no cause’ out for Sponsor Site: Usually a way for site to terminate to protect the safety of subjects Termination for breach: Material breach of agreement; provide opportunity to cure

  12. MAGI Approach • 12. Effective Date, Term & Termination • 12.1. Effective Date • This Agreement becomes effective when signed below by all parties, on the date of the last signature.[1] • 12.2. Term • Unless terminated earlier, this Agreement will expire when (a) Site has submitted all CRFs to Sponsor, has resolved all data clarification queries, and submitted the closeout report to the IRB and Sponsor; and (b) all payments, reimbursements and refunds have been made. • 12.3. Termination • The parties may terminate this Agreement under the following circumstances: Breach. Upon material breach by a party, the other party may terminate this Agreement provided that the other party fails to cure the breach within 20 days after notice.[1,2] Subject Safety. Either party may terminate immediately based on Subject safety or welfare concerns, e.g., if the informed consent form required by the IRB/IEC or other party is unacceptable, or if the IRB terminates the Study at the Site. Alternatively, Parties may agree that Site will discontinue enrolling Subjects and attempt to agree if and how the Study will proceed at the Site. Insolvency. Either party may terminate immediately upon notice by the other party that it has filed for protection under any bankruptcy laws, has been declared insolvent, ceases or threatens to cease to carry on its business, or an administrator or receiver has been appointed over all or part of its assets. Investigator Successor. Either party may terminate if Investigator is unable for any reason to continue in that role and the parties are unable to agree upon a successor. Government Exclusion. Site may terminate immediately if Sponsor is excluded from any FDA, OHRP or Medicare/Medicaid, or other state or federal government program. • [3]Without Cause. Either party may terminate without cause, upon 20 days’ prior notice. • [4]Upon termination, Site will immediately stop enrolling Subjects and, subject to protecting Subject safety and welfare, cease Study activities and complete its normal Study completion responsibilities.

  13. Governing Law/Venue Choice of law determines which state or country’s law should govern the contract Choice of venue determines where disputes are resolved State institution limited to their state laws Use: “without regard to its conflict of laws provisions” Silence – remove the clause Where is the work being done? Many states will apply this

  14. MAGI Approach • 14.1. Governing Law & Jurisdiction • The laws of _________ govern this Agreement. The Courts of ____________ have legal jurisdiction, without regard to conflict-of-laws provisions.[1,2,3,4,5,6,7]

  15. Assignment What is it? Ability to assign contract to another party May be prohibited or limited to written consent Issues: By institution/investigator Qualifications of new investigator/staff Indemnification, confidentiality and IP provisions enforceable against all parties By Sponsor/CRO Continuity of obligations Overall, ensure full assignment of responsibilities: Payment Study completion and reporting

  16. Negotiating and Drafting the Assignment and Delegation Provision: The Anti-Assignment Clause A Typical, but Flawed, Anti-Assignment Clause: “This Agreement shall not be assigned by either party without the consent of the other party”. A clause that prohibits solely the assignment of the contract, without any reference to rights under the contract, presumptively prohibits only the delegation of duties

  17. Contract Rights • Today, contract rights are freely assignable, with certain limited exceptions • This general rule completely reverses earlier common law doctrines and reflects, in large part, the role that contract rights play in a modern credit-based economy

  18. MAGI Approach • 14.7. Assignment • Any party may assign this Agreement to an Affiliate or in connection with the merger, consolidation or sale of all or substantially all of its assets, upon 30 days’ prior written notice to the other party, provided that the Affiliate or acquirer agrees to assume all responsibilities and obligations under this Agreement. Any other assignment of this Agreement, and the associated rights and obligations, requires the prior written consent of the other party. If Site or Investigator terminates this Agreement, it will assign to Sponsor its contracts with subcontractors, if any, so Sponsor can continue study without that party. • 14.8. Delegation • Site may delegate Investigator duties under this Agreement according to Section 3.6. Investigator may delegate his/her duties under this Agreement according to Section 3.8. The parties may delegate other duties under this Agreement to third-parties, provided, however, that (a) such third parties perform such duties in a manner consistent with this Agreement, and (b) the delegating party remains fully responsible for such third parties’ performance under this Agreement.[1]

  19. Entire Agreement/Modification What is it? Ensures that the contract represents the entire understanding of the parties with respect to the subject matter. Must incorporate protocol, exhibits, schedules, addendum, etc. Assures that assurances outside the contract are not enforceable. Issues with modifications: Must be in writing. Must be signed by proper parties. Must properly integrate with core agreement.

  20. Putting It All Together Contract Goals: • Record parties’ agreement • Merger provisions increases certainty in terms set forth

  21. MAGI Approach • 14.3. Entire Agreement; Modifications • This Agreement, together with any attachments or exhibits, sets forth the entire understanding among the parties about the Study. Any prior agreements, promises or representations, whether oral or written, such as agreements of confidentiality, have no force or effect. Any modification or waiver to this Agreement must be in writing and signed by all parties to this Agreement. However, IRB-approved changes to the Protocol are incorporated by reference into this Agreement, subject to agreement on appropriate budget modifications.[1]

  22. Contract Logistics Proof before you send/sign Copy/paste errors Templates getting switched Emails vs. Hard copy Who keeps signed originals?

  23. Post-termination Obligations • Return/destruction of confidential information • Safeguarding PHI • Return of case report forms, unused drug/device and related equipment and supplies • Surviving obligations (e.g., IP, use of name, confidentiality, indemnification)

  24. Thank you!

More Related